Department of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Rome, Italy.
Oncology Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Breast J. 2019 Mar;25(2):273-277. doi: 10.1111/tbj.13206. Epub 2019 Feb 7.
We evaluated the impact of breast cancer subtypes on pathologic complete response (pCR) in 181 patients with positive nodes undergoing neoadjuvant chemotherapy (NAC). After NAC, patients underwent surgery, with sentinel lymph node biopsy (SLNB) or axillary dissection (ALND). In 28.2% of cases a pCR was achieved, with the highest rate in Her2+ and triple negative tumors. Overall, nodal pCR was more frequent than breast pCR (P = 0.003) with higher percentages in Her2+ and LLB-Her2+ (P < 0.05). In the Her2+ group, nodal pCR was observed only with breast pCR. Thus, in Her2+ tumors, breast pCR predicts node pCR, supporting the use of SLNB in this subgroup to stage the axilla avoiding ALND.
我们评估了 181 例阳性淋巴结患者接受新辅助化疗（NAC）后乳腺癌亚型对病理完全缓解（pCR）的影响。NAC 后，患者行手术治疗，包括前哨淋巴结活检（SLNB）或腋窝清扫（ALND）。28.2%的患者达到了 pCR，其中 Her2+和三阴性肿瘤的 pCR 率最高。总体而言，淋巴结 pCR 比乳腺 pCR 更常见（P=0.003），Her2+和 LLB-Her2+的比例更高（P<0.05）。在 Her2+组中，仅观察到乳腺 pCR 伴有淋巴结 pCR。因此，在 Her2+肿瘤中，乳腺 pCR 预测淋巴结 pCR，支持在该亚组中使用 SLNB 分期腋窝，避免 ALND。
